Nonhealing skin lesions in a sailor and a journalist returning from Iraq

Cleveland Clinic Journal of Medicine

Volumn 72, Issue 2, 2005, Pages 93-106

  Lesho, Emil P ^a   Neafie, Ronald ^b   Wortmann, Glenn ^a   Aronson, Naomi ^c  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFALEXIN; DIETHYLTOLUAMIDE; FLUCONAZOLE; IMIDAZOLE; INSECT REPELLENT; ITRACONAZOLE; LESHCUTAN; LIPOSOME; LIQUID NITROGEN; MEGLUMINE ANTIMONATE; METHYLBENZETHONIUM CHLORIDE; PAROMOMYCIN; PERMETHRIN; PLACEBO; STIBOGLUCONATE SODIUM; ANTIMONY;

ANEMIA; ANOREXIA; ARMY; ARTHRALGIA; ARTHROPATHY; ARTHROPOD; BED NET; BLASTOMYCOSIS; CAUTERIZATION; CLINICAL FEATURE; CLINICAL TRIAL; CRYOTHERAPY; CULTURE MEDIUM; CURETTAGE; DEBRIDEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG APPROVAL; DRUG CAPSULE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; ECTHYMA; ELECTROCARDIOGRAPHY; ENVIRONMENTAL SANITATION; FATIGUE; GASTROINTESTINAL SYMPTOM; GEOGRAPHIC DISTRIBUTION; HEADACHE; HEALTH CARE PERSONNEL; HEMANGIOMATOSIS; HERPES ZOSTER; HUMAN; HYPERTHERMIC THERAPY; HYPOPIGMENTATION; IN VITRO STUDY; INFECTION PREVENTION; IRAQ; LEUKOPENIA; MICROSCOPY; MYALGIA; MYIASIS; NONHUMAN; PANCREATITIS; PARASITE TRANSMISSION; POLYMERASE CHAIN REACTION; PROFESSIONAL PRACTICE; PYOGENIC GRANULOMA; REVIEW; SAILOR; SARCOIDOSIS; SCAR FORMATION; SEROLOGY; SKIN ALLERGY; SKIN CANCER; SKIN DEFECT; SKIN LEISHMANIASIS; SKIN TEST; SPECIES DIFFERENCE; SPIDER BITE; SPOROTRICHOSIS; THROMBOCYTOPENIA; TRAVEL; TREATMENT WITHDRAWAL; UNITED STATES; VACCINATION; ADULT; CASE REPORT; FEMALE; MALE; MILITARY MEDICINE; PATHOPHYSIOLOGY; PUBLISHING; RECURRENT DISEASE; SOLDIER; WAR;

ADULT; ANTIMONY; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IRAQ; JOURNALISM; LEISHMANIASIS, CUTANEOUS; MALE; MILITARY MEDICINE; MILITARY PERSONNEL; RECURRENCE; WAR;

EID: 17844410107     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.72.2.93     Document Type: Review

References (46)

1. Caumes E, Carriere J, Guermonprez G, Bricaire F, Danis M, Gentilini M. Dermatoses associated with travel to tropical countries: a prospective study of the diagnosis and management of 269 patients presenting to a tropical disease unit. Clin Infect Dis 1995; 20:542-548.
2. Dowlati Y. Cutaneous leishmaniasis: clinical aspect. Clin Dermatol 1996; 14:425-431.
3. Desjeux P. Leishmaniasis: public health aspects and control. Clin Dermatol 1996; 14:417-423.
4. Centers for Disease Control and Prevention. Update: cutaneous leishmaniasis in U.S. military personnel - Southwest/Central Asia, 2002-2004. MMWR 2004; 53(12):264-265.
5. Weina PJ, Neafie RC, Wortmann G, Polhemus M, Aronson NE. Old World leishmaniasis: an emerging infection among deployed US military and civilian workers. Clin Infect Dis 2004; 39:1674-1680.
6. Reithinger R, Mohsen M, Addil K, et al. Anthroponotic cutaneous leishmaniasis, Kabul Afghanistan. Emerg Infect Dis 2003; 9:727-729.
7. Locksley RM, Heinzel FP, Sadick MF, Holaday BJ, Gardner KD Jr. Murine cutaneous leishmaniasis: susceptibility correlates with differential expansion of helper T-cell subsets. Ann Inst Pasteur Immunol 1987; 138:744-749.
8. Magill AJ, Grogl M, Gasser RA, Sun W, Oster CN. Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm. N Engl J Med 1993; 328:1383-1387.
9. Herwaldt BL. Leishmaniasis. Lancet 1999; 354:1191-1199.
10. Armed Forces Institute of Pathology. Cutaneous leishmaniasis (CL). www.afip.org/Departments/infectious/index.html. Accessed December 1, 2004.
11. Navin TR, Arana FE, de Merida AM, Arana BA, Castillo AL, Silvers DN. Cutaneous leishmaniasis in Guatemala: comparison of diagnostic methods. Am J Trop Med Hyg 1990; 42:36-42.
12. Dedet JP, Pratlong F. Leishmaniasis. In: Cook G, Zumla A, editors. Manson's Tropical Diseases. 21st ed. London; Elsevier Science Limited; 2003:1339-1364.
13. Neva F, Sacks D. Leishmaniasis. In: Warren K, Mahmoud AAF, editors. Tropical and Geographical Medicine. 2nd ed. New York; McGraw-Hill, Inc; 1990:296-308.
14. Personal communication. P. McEvoy, Armed Forces Institute of Pathology, Washington, DC; April 2004.
15. Vega-Lopez F. Diagnosis of cutaneous leishmaniasis. Curr Opin Infect Dis 2003; 16:97-101.
16. Wortmann G, Sweeney C, Houng HS, et al. Rapid diagnosis of leishmaniasis using fluorogenic polymerase chain reaction. Am J Trop Med Hyg 2001; 65:583-587.
17. Griffiths WAD, Croft SL. Cutaneous leishmaniasis. Postgrad Doctor Mid East 1980; 3:388-394.
18. Personal communication. Dr. Barbara Herwaldt, CDC. December 3, 2004.
19. Aronson NE, Wortmann GW, Johnson SC, et al. Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent U.S. military experience. Clin Infect Dis 1998; 27:1457-1464.
20. Gasser RA Jr, Magill AJ, Oster CN, Franke ED, Grogl M, Berman JD. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis 1994; 18:83-90.
21. McBride MO, Linney M, Davidson RN, Weber JN. Pancreatic necrosis following treatment of leishmaniasis with sodium stibogluconate. Clin Infect Dis 1995; 21:710.
22. Centers for Disease Control and Prevention. Informational Material for Physicians from the Centers for Disease Control and Prevention about Pentostam (Sodium Stibogluconate). Atlanta, GA: CDC Drug Services; August 19, 1995. CDC publication 0303.
23. Pentostam [package insert]. Uxbridge, UK; GlaxoSmithKline. 2003.
24. Chulay JD, Spencer HG, Mugambi M. Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate). Am J Trop Med Hyg 1985; 34:702-709.
25. Wortmann G, Miller R, Oster C, et al. A randomized, double-blind study of the efficacy of a 10- or-20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Clin Infect Dis 2002; 35:261-267.
26. Reithinger R, Mohsen M, Kolaczinksi J, Davies CR, David JR. A randomized controlled trial to test the efficacy of thermotherapy against Leishmania tropica in Kabul, Afghanistan. Abstract #776 in vol 69, No 3 Program and Abstracts of the 52nd Annual Meeting of the American Society of Tropical Medicine and Hygiene. Philadelphia, PA. December 3-7, 2003.
27. Ballou WR, McClain JB, Gordon DM, et al. Safety and efficacy of high-dose sodium stibogluconate therapy of American cutaneous leishmaniasis. Lancet 1987; 2(8549):13-16.
28. Wortmann GW, Fraser SL, Aronson NE, et al. Failure of amphotericin B lipid complex in the treatment of cutaneous leishmaniasis. Clin Infect Dis 1998; 26:1006-1007.
29. Tempone AG, Perez D, Rath S, Vilarinho AL, Mortara RA, de Andrade HF Jr. Targeting Leishmania (L.) chagasi amastigotes through macrophage scavenger receptors: the use of drugs entrapped in liposomes containing phosphatidylserine. J Antibicrob Chemother 2004; 54:60.
30. Alkhawajah A. Recent trends in the treatment of cutaneous leishmaniasis. Ann Saudi Med 1998; 18:412-416.
31. Navin TR, Arana BA, Arana FE, Berman JD, Chajon JF. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992; 165:528-534.
32. Momeni AZ, Jalayer T, Emamjomeh M. Treatment of cutaneous leishmaniasis with itraconazole. Randomized double-blind study. Arch Dermatol 1996; 132:784-786.
33. Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002; 346:891-894.
34. El-On J, Livshin R, Even-Pas Z, Hamburger D, Weinrauch L. Topical treatment of cutaneous leishmaniasis. J Invest Dermatol 1986; 87:284-288.
35. Soto J, Fuya P, Herera R, Berman J. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonite as treatment for American cutaneous leishmaniasis: controlled study. Clin Infect Dis 1998; 26:56-58.
36. Alkhawaja AM, Larbi E, Al-Gindan Y, Abahussein A, Jain S. Treatment of cutaneous leishmaniasis with antimony: intramuscular vs. intralesional administration. Ann Trop Med Parasitol 1997; 91:899-905.
37. Asilian A, Sadeghinia A, Faghihi G, Momeni A, Amini Harndi A. The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis. Ann Trop Med Parasitol 2003; 97:493-498.
38. Asilian A, Sadeghinia A, Faghihi G, Momeni A. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol 2004; 43:281-283.
39. Berman JD. Human leishmaniasis: clinical, diagnostic and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997; 24:684-703.
40. Bassiony A, El-Mashad M, Talaat M, Kutty K, Metaawa B. Cryotherapy in cutaneous leishmaniasis. Br J Dermatol 1982; 107:467-474.
41. Al-Gindan Y, Kubba R, Omer AH, el-Hassan AM. Cryosurgery in old world cutaneous leishmaniasis. Br J Dermatol 1988; 188:851-854.
42. Navin TR, Arana BA, Arana FE, de Merida AM, Castillo AL, Pozuelos JL. Placebo-controlled clinical trial of meglumine antimonate (Glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. Am J Trop Med Hyg 1990; 42:43-50.
43. Fradin MS. Mosquitoes and mosquito repellents - a clinician's guide. Ann Intern Med 1998; 120:931-940.
44. Greenblatt CL. Cutaneous leishmaniasis: the prospects for a killed vaccine. Parasitol Today 1988; 4:53-54.
45. Modabber F. Development of vaccines against leishmaniasis. Scand J Infect Dis 1990; 76:72-78.
46. Sylvester RD. Blood donor deferral for leishmaniasis in Iraq. www-nehc.med.navy.mil/downloads/prevmed/leishmanAug03.pdf. Accessed December 1, 2004.